Research reviewed by Gram found that a national panel of 16 clinicians agreed on 13 recommendations for monitoring and treating bone health in adults with Duchenne muscular dystrophy. The guidelines focus on fracture risk, bone density scans, vitamin D and hormone status, specialist referral, and reviewing long-term medicines during the move from children’s to adult care.
Adults with Duchenne muscular dystrophy, a rare inherited condition that gradually weakens muscles, often have weak bones and break bones more easily. Many took bone-strengthening medicines called bisphosphonates as children or teens, then move into adult healthcare, where guidance has been limited. According to research reviewed by Gram, a panel of 16 clinicians used a modified Delphi process, in which experts vote on statements over several rounds until they reach agreement, to create 13 recommendations. The guidelines cover how to assess fracture risk, when to use bone density scans, how to check vitamin D and hormone levels, when to refer patients to a bone specialist, and how to review long-term medicines during the move to adult care. The experts stressed individualized decisions, because bone imaging can be technically tricky and the evidence for adults with this condition is still small. These recommendations offer a practical starting point, not a substitute for a personal care plan.
Key Statistics
A 2026 Delphi consensus study published in the journal Bone found that 16 clinicians agreed on 13 recommendations for bone health in adults with Duchenne muscular dystrophy.
In the 2026 Bone consensus study on adults with Duchenne muscular dystrophy, a recommendation was accepted only when at least 80% of the 16 clinicians scored it 7 to 9 on a 9-point agreement scale.
The Quick Take
- What they studied: How doctors should monitor and treat bone health in adults with Duchenne muscular dystrophy, especially when patients move from children’s care to adult care.
- Who participated: A panel of 16 clinicians from across the country who specialize in muscle or bone conditions. The team also reviewed existing medical literature, a survey of clinicians, and input from adults with Duchenne and their caregivers.
- Key finding: The panel agreed on 13 recommendations. To count as agreed, at least 80% of panelists had to score a statement 7 to 9 on a 9-point scale, which shows strong expert support even though the evidence in adults is limited.
- What it means for you: If you or someone you care for has Duchenne, these guidelines suggest asking the care team about bone fracture risk, bone density scans, vitamin D and hormone levels, and a review of past bone medicines. Treatment decisions should be individualized with a doctor who knows your situation.
The Research Details
This study created national expert guidelines rather than testing a treatment on patients. The research team first reviewed published medical studies on bone health in Duchenne, then surveyed clinicians about how they currently care for these patients. They also gathered input from adults with Duchenne and their family caregivers, so the guidelines reflect real-life concerns.
To turn this information into guidelines, the team used a modified Delphi process. In this method, experts receive draft statements, vote on how strongly they agree, read the group’s responses, and vote again. The process repeats until the group reaches a clear consensus. Here, a statement counted as agreed only when at least 80% of the 16 clinicians scored it 7 to 9 on a 9-point scale.
The final step was a discussion among a multidisciplinary expert group, which included clinicians from different specialties. This helped the team translate the votes into practical advice that adult doctors can use in clinic.
Delphi consensus studies are useful when strong clinical trials are not yet available. Duchenne is rare, so large studies of adults are difficult to run. A structured expert vote gives doctors a shared, transparent starting point while newer research is still being done.
Because the process includes patient and caregiver input, the guidelines address practical problems, such as scan difficulties and the burden of long-term medicines, that might be missed in a purely research-based review.
The method is well established and transparent, and the consensus threshold was clearly defined in advance. The guidelines were developed by a multidisciplinary group and informed by a literature review, a clinician survey, and patient and carer input.
However, the panel was small at 16 clinicians, and expert consensus is not the same as proof from clinical trials. Readers should treat these recommendations as strong expert advice rather than final scientific answers.
What the Results Show
The panel agreed on 13 recommendations covering several areas of bone care. These include how to estimate fracture risk, when to use DXA bone density scans, and how to monitor for spine fractures, which can happen without obvious symptoms. The guidelines also address checking vitamin D and sex hormone levels, since low levels can affect bone strength.
Other recommendations focus on when to refer a patient to a bone specialist, how to start and review osteoporosis medicines, and what to do if a treatment does not seem to be working. The panel emphasized that these steps should be tailored to each person rather than applied the same way to everyone.
A key area is the transition from pediatric to adult care. The guidelines recommend a structured review of long-term therapies, such as bisphosphonates started in childhood, so that adult doctors can decide whether to continue, adjust, or stop them based on the patient’s current situation.
The experts noted that bone imaging can be technically difficult in people with Duchenne, partly because of body changes from muscle loss and past treatments. This means scan results need careful interpretation. The panel also highlighted that fractures can seriously affect daily function, mobility, and independence, so preventing them matters beyond the numbers on a scan.
The guidelines also recognize the cumulative burden of treatment. Years of medicine use, along with the everyday demands of living with a progressive condition, mean that decisions should consider quality of life as well as bone measurements.
Bone health guidance for children with Duchenne is already well established. This study fills a gap by focusing on adults, who have been far less studied. Earlier work has largely described bone problems in this group, while these consensus recommendations turn that knowledge into a practical framework for adult clinics.
The recommendations also fit with general osteoporosis principles used in other populations, but they adapt those principles to the unique features of Duchenne, such as reduced movement, delayed puberty, and long-term steroid use.
The most important limitation is the small number of experts, 16 clinicians, who voted on the statements. Their views may not match every specialist’s approach. Expert consensus also cannot prove that following these recommendations will prevent fractures. Testing that would require long-term studies that do not yet exist for adults with Duchenne.
The panel itself noted that adult-specific evidence is limited, so many recommendations rely on expert judgment and on evidence from other groups. The guidelines are meant to be flexible, which means individual doctors still need to make decisions based on each patient.
The Bottom Line
Research shows that a national expert panel agreed on 13 recommendations for bone care in adults with Duchenne. Confidence in these recommendations is moderate to strong for the panel’s agreement, but moderate for the underlying evidence, because high-quality studies in adults with Duchenne are still lacking. Patients should discuss with their care team how these recommendations apply to them.
These guidelines are most relevant for adults with Duchenne, their caregivers, and the neuromuscular and bone clinicians who treat them. They are also useful for adult doctors receiving patients from pediatric clinics. People who do not have Duchenne or other muscle-weakening conditions should not apply these specific recommendations without advice from their own doctor.
Clinical guidelines like these shape care over months and years rather than days. Changes in bone monitoring, medicine review, or specialist referral may take several months to set up. Bone density changes typically develop slowly, so any benefit from improved care would generally be seen over a longer period, and results should be reviewed regularly with a doctor.
Frequently Asked Questions
What bone health recommendations exist for adults with Duchenne muscular dystrophy?
A national expert panel of 16 clinicians agreed on 13 recommendations. They cover fracture risk assessment, bone density scans, spine fracture monitoring, vitamin D and hormone checks, specialist referral, and reviewing osteoporosis medicines during the transition to adult care.
Why are bones weaker in people with Duchenne muscular dystrophy?
Bones may weaken because of progressive muscle loss, reduced movement, delayed puberty or low sex hormone levels, and long-term steroid use. The Bone journal study describes these factors as working together, which is why fracture risk can be higher in this group.
How did experts decide which bone health recommendations to include?
Experts used a modified Delphi process, voting on draft statements over several rounds. A recommendation was accepted when at least 80% of the 16 clinicians scored it 7 to 9 on a 9-point scale, showing strong agreement among specialists.
Should adults with Duchenne stop bisphosphonate medicine when they move to adult care?
The guidelines recommend a structured review of long-term bisphosphonate therapy during transition rather than an automatic stop or continuation. Decisions should be individualized, considering fracture history, bone scan results, and the patient’s overall situation, and made with the adult care team.
Want to Apply This Research?
- Log the dates of bone density scans, vitamin D and hormone blood test results, and any fractures or near-falls. Record the name, dose, and start date of each bone medicine so the full treatment history is easy to share at appointments.
- Use the app to prepare a short question list before each clinic visit. Include questions about fracture risk, the need for a scan, whether vitamin D or hormone levels should be checked, and whether any long-term medicines should be reviewed during the move to adult care.
- Track bone-related events and appointments on a monthly and yearly basis. Monthly entries can note mobility changes, pain, or falls. Yearly entries can capture scan dates, lab results, and treatment reviews, creating a long-term record that supports conversations with the adult care team as needs change.
This article summarizes an expert consensus study on bone health in adults with Duchenne muscular dystrophy. It is for general information only and does not replace advice from a doctor or specialist. Medicine decisions, including starting, changing, or stopping bisphosphonates or other bone treatments, should be made with a qualified healthcare provider who knows your full medical history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.